Careers Contact Locations

OPKO Health, Inc.

  • Home
  • Who We Are
    • Our Vision
    • Our History
    • Our Leadership
  • What We Do
    • Overview
    • Our Products
    • Our Solutions
    • Our Technology
    • Our Research
    • Our Diagnostics
  • News & Media
    • Press Releases
    • Announcements
    • Events
    • Presentations
    • Fact Sheets
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact
  • Locations

Press Releases

News & Media

News & Media

  • Press Releases
  • Announcements
  • Events
  • Presentations
  • Fact Sheets

OPKO Health Submits De Novo Request to the U.S. FDA for the 4Kscore® Test

Jun 20, 2019

OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results

May 7, 2019

OPKO Health to Report First Quarter 2019 Financial Results on May 7, 2019

Apr 30, 2019

OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial

Apr 12, 2019

OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial

Mar 21, 2019

OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results

Feb 27, 2019

OPKO Health to Announce Fourth Quarter 2018 Financial Results on February 27, 2019

Feb 26, 2019

OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes

Feb 5, 2019

OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes

Feb 4, 2019

OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer

Feb 1, 2019
RSS
  • Prev
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...42
    Next
    © 2021 OPKO Health, Inc. All Rights Reserved.
    Privacy Policy Governance Terms of Use Sitemap